Panayotides P, Lenkei R, Porwit A, Reizenstein P
Med Oncol Tumor Pharmacother. 1986;3(3-4):255-63. doi: 10.1007/BF02935002.
Interleukin-2 (IL-2) for a long time has been considered as a T-cell specific growth factor which acts through distinct surface receptors present on activated, but not on resting, T-lymphocytes. Recently it has been shown that activated murine and human B-cells also express IL-2 receptors and respond to IL-2 with an increase of DNA synthesis. Some human B-cell malignancies have been reported to react with anti-IL-2 receptor antibodies, but no response to IL-2 has been documented in these cases. Here, in five of 11 B-cell leukemia/lymphoma cases, we identified cells which not only express the IL-2 receptor, but also respond to IL-2 stimulation, as shown by a marked increase of 3H-thymidine incorporation and by differentiation of lymphoma cells. The IL-2-induced 3H-thymidine uptake was completely blocked by a monoclonal antibody to IL-2 receptor, which indicates that IL-2 acted directly through functional IL-2 receptors.
长期以来,白细胞介素-2(IL-2)一直被认为是一种T细胞特异性生长因子,它通过活化的而非静止的T淋巴细胞表面存在的独特受体发挥作用。最近研究表明,活化的鼠源和人源B细胞也表达IL-2受体,并对IL-2作出反应,使DNA合成增加。据报道,一些人类B细胞恶性肿瘤会与抗IL-2受体抗体发生反应,但在这些病例中尚未记录到对IL-2的反应。在此,在11例B细胞白血病/淋巴瘤病例中的5例中,我们鉴定出不仅表达IL-2受体,而且对IL-2刺激有反应的细胞,这表现为3H-胸腺嘧啶核苷掺入显著增加以及淋巴瘤细胞分化。抗IL-2受体单克隆抗体完全阻断了IL-2诱导的3H-胸腺嘧啶核苷摄取,这表明IL-2是通过功能性IL-2受体直接发挥作用的。